Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315211 · ClinicalTrials.gov registry record · Phase 2
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
A Phase 2 study, sponsored by Aultman Health Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00315211: Clinical Trial Phase 2 study, sponsored by Aultman Health Foundation.
NCT00315211 is a Phase 2 study that was terminated before completion, run by Aultman Health Foundation. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00315211, a Phase 2 study, was terminated before completion, sponsored by Aultman Health Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
Primary Outcome
To determine the overall response rate of patients treated with at least two cycles of topotecan and docetaxel
Interventions
- DRUG Intravenous Topotecan
- DRUG Intravenous Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-11-08 |
| Phase | Phase 2 |
Why NCT00315211 stopped before completion
NCT00315211 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Intravenous Topotecan is the first listed.
NCT00315211 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00315211 about?
NCT00315211 is a clinical study titled "Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer". The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
What is the current status of trial NCT00315211?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2004-11. Estimated completion is 2007-11-08.
What interventions are being tested in trial NCT00315211?
The interventions under investigation include: Intravenous Topotecan (DRUG), Intravenous Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00315211?
This trial is sponsored by Aultman Health Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00315211's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia